Hyperbaric Oxygen Treatment for Opioid Use Disorder

MW
Overseen ByMarian Wilson, PhD
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Washington State University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 3 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests whether hyperbaric oxygen therapy (HBOT)—breathing pure oxygen in a pressurized room—can help reduce methadone doses by easing opioid withdrawal symptoms. It compares two different oxygen pressures to a placebo treatment. Individuals on methadone in a supervised opioid treatment program who wish to lower their dose may be suitable candidates, especially if withdrawal symptoms disrupt daily life. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this innovative therapy.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are taking Antabuse for alcohol addiction.

What prior data suggests that hyperbaric oxygen treatment is safe for opioid use disorder?

Research has shown that hyperbaric oxygen treatment (HBOT) could be a safe option for individuals undergoing opioid withdrawal. In earlier studies, participants who received HBOT at various pressure levels reported less pain and fewer drug cravings. These studies did not identify any major safety concerns, indicating that the treatment is generally well-tolerated.

During HBOT, participants breathe 100% oxygen in a pressurized chamber. This method is used in other treatments and is typically considered safe. Some minor side effects, such as ear discomfort, might occur due to pressure changes, but no serious issues were reported in the studies.

Overall, this treatment appears well-tolerated and offers a non-drug option to help reduce opioid use.12345

Why are researchers excited about this trial's treatments?

Researchers are excited about hyperbaric oxygen treatment (HBOT) for opioid use disorder because it offers a novel approach compared to traditional therapies like medication-assisted treatments (MAT) with methadone, buprenorphine, or naltrexone. Unlike these standard medications that work by interacting with opioid receptors to reduce cravings and withdrawal symptoms, HBOT involves administering 100% oxygen at increased atmospheric pressures, which may promote brain healing and reduce dependency. This method is particularly intriguing because it targets the brain's recovery in a physical way, potentially offering benefits beyond just managing symptoms. With the potential to aid in neural repair and enhance recovery, HBOT represents a fresh avenue for treating opioid use disorder.

What evidence suggests that hyperbaric oxygen treatment might be an effective treatment for opioid use disorder?

Research shows that hyperbaric oxygen therapy (HBOT) might help ease symptoms of opioid withdrawal. In this trial, participants will join different treatment arms. Some will receive full HBOT, involving 100% oxygen at 2.0 ATA, while others will receive a partial pressure treatment with 100% oxygen at 1.3 ATA. A sham treatment arm will provide participants with 21% oxygen at 1.3 ATA. Studies have found that patients who received full HBOT reported better pain management and fewer drug cravings than those who received a sham treatment. HBOT has been particularly effective in reducing withdrawal symptoms and helping patients decrease their methadone doses. Early findings suggest that HBOT sessions lasting 90 minutes on two consecutive days can significantly improve the withdrawal experience. Overall, these initial results are promising for using HBOT as a supportive treatment for opioid use disorder.12345

Who Is on the Research Team?

LM

Layton Matt, MD

Principal Investigator

Washington State University

Are You a Good Fit for This Trial?

This trial is for adults over 18 who are enrolled in a supervised opioid treatment program at the Spokane Regional Health District. Participants must be able to read, speak, and write English and provide written informed consent.

Inclusion Criteria

Enrollment in a supervised opioid treatment program at the Spokane Regional Health District
I am older than 18 years.
Ability to provide written informed consent.
See 1 more

Exclusion Criteria

I have emphysema.
Air cysts in the lung
I do not have any mental health conditions that would make it unsafe for me to participate.
See 5 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive hyperbaric oxygen therapy (HBOT) at different pressures or sham treatment during methadone tapering

4 weeks
Weekly visits for HBOT sessions

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks
2 visits (in-person)

Long-term follow-up

Participants' methadone dose changes are assessed at one month and three months from baseline

3 months

What Are the Treatments Tested in This Trial?

Interventions

  • Hyperbaric Oxygen Treatment
Trial Overview The study tests if hyperbaric oxygen therapy (HBOT) can help with physical and psychological symptoms of opioid withdrawal during methadone dose reduction compared to a sham treatment. It also examines HBOT's role in increasing success rates of tapering off opioids.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Full treatmentExperimental Treatment1 Intervention
Group II: Partial pressure treatmentActive Control1 Intervention
Group III: ShamPlacebo Group1 Intervention

Hyperbaric Oxygen Treatment is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Hyperbaric Oxygen Therapy for:
🇪🇺
Approved in European Union as Hyperbaric Oxygen Therapy for:
🇨🇦
Approved in Canada as Hyperbaric Oxygen Therapy for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Washington State University

Lead Sponsor

Trials
114
Recruited
58,800+

Published Research Related to This Trial

Mice that developed tolerance to opioid agonists showed a reduced pain-relieving response to hyperbaric oxygen (HBO2) therapy, indicating that opioid receptors play a role in the analgesic effects of HBO2.
The study found that both μ-opioid and κ-opioid receptors are involved in mediating the acute pain relief provided by HBO2, suggesting that this therapy may be less effective in patients who are tolerant to opioids.
Reduced antinociceptive responsiveness to hyperbaric oxygen in opioid-tolerant mice.Zhang, Y., Stolz, PA., Shirachi, DY., et al.[2015]
The most common side effects of hyperbaric oxygen (HBO2) therapy are middle ear barotrauma, affecting up to 2% of patients, which can be managed through techniques like autoinflation or tympanostomy tubes.
While rare, more severe side effects from HBO2 therapy can include oxygen toxicity leading to issues like progressive myopia and pulmonary dyspnea, with serious complications like seizures occurring at higher oxygen pressures, particularly in patients with acidosis.
Side effects of hyperbaric oxygen therapy.Camporesi, EM.[2014]
Hyperbaric oxygen therapy (HBOT) is associated with a higher incidence of adverse effects (30.11%) compared to control groups (10.43%), particularly when the treatment involves more than 10 sessions or chamber pressures exceed 2.0 ATA.
The most common side effect reported was ear discomfort, indicating that while HBOT can be beneficial, careful monitoring for adverse reactions is necessary, especially under specific conditions.
Adverse effects of hyperbaric oxygen therapy: a systematic review and meta-analysis.Zhang, Y., Zhou, Y., Jia, Y., et al.[2023]

Citations

1.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/35393218/
Hyperbaric Oxygen Therapy for Pain, Opioid Withdrawal, ...All measurements improved more, on average, for participants receiving full-dose HBOT treatment than among participants receiving sham ...
Hyperbaric Oxygen Therapy for Pain, Opioid Withdrawal ...Two consecutive days of hyperbaric oxygen therapy in 90 minute sessions showed promising trends in improving pain, drug craving, and reported withdrawal ...
Hyperbaric oxygen treatment attenuates naloxone ...The present study demonstrates that HBOT is an effective intervention for reducing somatic morphine withdrawal symptoms in both male and female ...
Hyperbaric Oxygen Treatment (HBOT) During Methadone ...The aims of this study are to 1) explore the efficacy of hyperbaric oxygen therapy (HBOT) applied at two different pressures compared to sham treatment in ...
Hyperbaric oxygen therapy shows promise for opioid ...Hyperbaric oxygen therapy may help people being treated for opioid addiction reduce their methadone dose and better manage pain and withdrawal ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security